These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284 [TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. Senoo K; Lip GY Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085 [TBL] [Abstract][Full Text] [Related]
5. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ; Trials; 2015 Sep; 16():393. PubMed ID: 26340977 [TBL] [Abstract][Full Text] [Related]
6. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M; Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865 [TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants in non-valvular atrial fibrillation. Potpara TS; Lip GY Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900 [TBL] [Abstract][Full Text] [Related]
8. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. Garcia DA Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997 [TBL] [Abstract][Full Text] [Related]
9. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. Renda G; di Nicola M; De Caterina R Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790 [TBL] [Abstract][Full Text] [Related]
10. Antithrombotic treatment in atrial fibrillation. Lip GY; Boos CJ Postgrad Med J; 2008 May; 84(991):252-8. PubMed ID: 18508982 [TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. Liew A; Eikelboom JW; O'Donnell M Curr Opin Cardiol; 2012 Jul; 27(4):331-9. PubMed ID: 22573171 [TBL] [Abstract][Full Text] [Related]
12. Emerging Tools for Stroke Prevention in Atrial Fibrillation. Voukalis C; Lip GY; Shantsila E EBioMedicine; 2016 Feb; 4():26-39. PubMed ID: 26981569 [TBL] [Abstract][Full Text] [Related]
13. Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. Zoppellaro G; Granziera S; Padayattil Jose S; Denas G; Bracco A; Iliceto S; Pengo V Expert Opin Drug Saf; 2015 May; 14(5):683-95. PubMed ID: 25803739 [TBL] [Abstract][Full Text] [Related]
14. Prevention of stroke in patients with atrial fibrillation. Olsson SB; Halperin JL Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916 [TBL] [Abstract][Full Text] [Related]
15. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY; Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063 [TBL] [Abstract][Full Text] [Related]
16. Prevention of cardioembolic stroke in patients with atrial fibrillation. Weber R; Diener HC; Weimar C Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1405-15. PubMed ID: 20936927 [TBL] [Abstract][Full Text] [Related]
17. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Zirlik A; Bode C J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543 [TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
19. New oral anticoagulants in elderly patients. Barco S; Cheung YW; Eikelboom JW; Coppens M Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909 [TBL] [Abstract][Full Text] [Related]
20. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. Szapary L; Fehér G; Bosnyák E; Deli G; Csécsei P Ideggyogy Sz; 2013 May; 66(5-6):165-74. PubMed ID: 23909016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]